Provided by Tiger Trade Technology Pte. Ltd.

Repligen

181.13
+0.84000.47%
Post-market: 181.00-0.1300-0.07%19:30 EDT
Volume:1.10M
Turnover:198.19M
Market Cap:10.20B
PE:248.12
High:182.43
Open:179.66
Low:175.75
Close:180.29
52wk High:188.73
52wk Low:100.99
Shares:56.29M
Float Shares:53.32M
Volume Ratio:1.05
T/O Rate:2.06%
Dividend:- -
Dividend Rate:- -
EPS(TTM):0.7300
EPS(LYR):0.8600
ROE:1.99%
ROA:1.40%
PB:4.83
PE(LYR):210.62

Loading ...

Sector Update: Healthcare Stocks Softer Late Afternoon

MT Newswires Live
·
Jul 23

Hold Rating Maintained as Repligen Acquisition Caps BioLife Upside; Price Target Cut to $31 from $33

TIPRANKS
·
Jul 22

Repligen to Acquire BioLife, Expanding Cell Therapy Reach

TIPRANKS
·
Jul 22

Repligen Corp: if Deal Terminated Under Some Circumstances, Biolife May be Required to Pay Repligen a Termination Fee of $59 Mln

THOMSON REUTERS
·
Jul 22

Shares of Biolife up 3.1% Premarket After $1.5 Billion Repligen Buyout

THOMSON REUTERS
·
Jul 22

Repligen Down 2.7%

THOMSON REUTERS
·
Jul 22

Repligen Beefs up Cell Therapy Business with $1.5 Billion Deal for Biolife

Reuters
·
Jul 22

Repligen to Buy Biolife Solutions for About USD 1.5 Billion, Offers USD 31 a Share

Reuters
·
Jul 22

Biolife Solutions - Repligen to Buy Biolife for $1.50 Bln Enterprise Value, 64% Stock, 36% Cash

THOMSON REUTERS
·
Jul 22

Biolife Solutions - Repligen Preliminary Q2 Reported Revenue Growth 12%, Organic Revenue Growth 13%

THOMSON REUTERS
·
Jul 22

Biolife Solutions - Stockholders to Receive $11.25 Cash and 0.1442 Repligen Shares Per Biolife Share

THOMSON REUTERS
·
Jul 22

Biolife Solutions - Preliminary Q2 Revenue Growth 21% Year-over-year

THOMSON REUTERS
·
Jul 22

Repligen to Acquire Biolife Solutions, Expanding Its Cell Therapy Capabilities with Market Leading Biopreservation Media

THOMSON REUTERS
·
Jul 22

Biolife Solutions - Repligen Expects at Least $20 Mln Synergies in Year One, $30 Mln in Year Two

THOMSON REUTERS
·
Jul 22

Repligen to Acquire BioLife Solutions, Expanding Its Cell Therapy Capabilities with Market Leading Biopreservation Media

GlobeNewswire
·
Jul 22

Earnings Preview: Repligen revenue is expected to increase by 15%, and institutional views are constructive

Earnings Agent
·
Jul 21

Repligen CFO Jason K. Garland Sells 530 Common Shares for $79,500

Reuters
·
Jul 18

Repligen to Report Second Quarter 2026 Financial Results

GlobeNewswire
·
Jul 15

Repligen Stock And 2 Dollar Beneficiaries Gaining Attention After Fed Rate Shift

Simply Wall St.
·
Jul 13

Can Repligen (RGEN) Stay Undervalued On Russell Index Removals And Margin Concerns?

Simply Wall St.
·
Jul 10